A Phase 1 interventional study of Belumosudil Tablet and Belumosudil Capsule in Bioavailability, sponsored by Kadmon Corporation, LLC. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-25.
Sponsored by Kadmon Corporation, LLC (part of Sanofi) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Phase 1 bioavailability study to evaluate the pharmacokinetics (PK) and tolerability/safety of the belumosudil tablet formulation in the fasted and fed states and compared to the belumosudil capsule formulation in the fed state.
This is a Phase 1, 3-way, crossover, randomized, open-label study in healthy subjects designed to compare the bioavailability of belumosudil (previously known as KD025) tablet formulation administered in the fed and fasted states and to assess the relative bioavailability of belumosudil tablet and capsule formulations in the fed state.
The primary objective of the study is to determine the PK parameters of belumosudil tablet formulation in the fed and fasted states.
The secondary objectives of the study are: (1) to assess the relative bioavailability of a tablet (test) to capsule (reference formulation of belumosudil; (2) to assess and compare the variability in the maximum concentration (Cmax) and area under the concentration-time curve (AUC) for belumosudil treatments (belumosudil 200 mg tablet in the fasting state, belumosudil 200 mg tablet in the fed state, and belumosudil as two 100 mg capsules in the fed state); and (3) to provide additional safety and tolerability information for belumosudil.
This is a single-center, open-label, randomized, single-dose, 3-period, 3-way, crossover study in healthy subjects.
In each of 3 study periods, each subject receives 1 of the following single-dose treatments:
Subjects are randomized to receive 1 dose of investigational product (IP; belumosudil tablet or capsule) in the morning of Day 1 in a randomized manner following an overnight fast or a high-fat breakfast. Administration is performed on Day 1 with an appropriate interval between subjects based on logistical requirements. Start time is determined based on logistics.
Subjects undergo a screening visit in the 21 days preceding first dose. Subjects are admitted to the clinical unit on the evening prior to dosing (Day -1), remain on site until 24 hours post-dose, and return to the clinic at 36 and 48 hours post-dose for PK assessments.
There is a minimum washout period of 6 days between each dose administration. All other meals are standardized for each of the in-clinic phases of the 3 treatment periods. Each period follows the same study design.
The randomized cohorts for the 3-periods were as follows:
A follow-up call is made 3 to 5 days after the final dose of IP.
Planned enrollment is 24 subjects to insure there are 20 evaluable subjects. A subject is considered evaluable if (s)he completes treatment with fasted and fed tablet formulations (Regimens A and B) without major protocol deviations.
Kadmon Corporation, LLC is the lead sponsor of 20 studies on the registry; none are open to participants now.
First submitted before Kadmon Corporation, LLC became part of Sanofi.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible for study entry subjects has to satisfy all of the following criteria:
Exclusion Criteria
Subjects are excluded from the study if one of more of the following statements is applicable:
Subject had a history or presence of any of the following:
Additional Restrictions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single-dose belumosudil 200 mg tablet in the fasted state
Drug: Belumosudil Tablet
Single-dose belumosudil 200 mg tablet in the fed state
Drug: Belumosudil Tablet
Single-dose belumosudil capsules (administered as two 100-mg capsules) in the fed state
Drug: Belumosudil Capsule
Also known as: Rezurock (brand), SLx-2119
Also known as: Rezurock (brand), SLx-2119
Pharmacokinetics: Cmax of Dosing Regimen A (Tablets--Fasting) vs. Dosing Regimen B (Tablets--Fed) for KD025, KD025m1, and KD025m2 at 48 Hours Post-dose
Maximum concentration (Cmax) of parent drug (KD025), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) when administering a single dose of belumosudil 200 mg tablet to subjects who are fasting (Regimen A) compared to administering a single dose of belumosudil 200 mg tablet to subjects who are fed (Regimen B) at 48 hours after dosing
Time frame: Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose
Pharmacokinetics: AUCs of Dosing Regimen A (Tablets--Fasting) vs. Dosing Regimen B (Tablets--Fed) for KD025, KD025m1, and KD025m2 at 48 Hours Post-dose
Area under concentration-time curve from zero to last dose of belumosudil 200 mg tablets (AUC\[0-last\]) and from zero to infinity (AUC\[0-inf\]) for Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) when administering a single dose of belumosudil 200 mg tablet to subjects who are fasting (Regimen A) compared to administering a single dose of belumosudil 200 mg tablet to subjects who are fed (Regimen B) at 48 hours after dosing
Time frame: Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose
Pharmacokinetics: Cmax for the Relative Bioavailability of Regimen B/Regimen A and Regimen B/Regimen C by Ratio of the Adjusted Geometric Means at 48 Hours Post-dose
Analysis of the maximum concentration (Cmax) of the relative bioavailability of Regimen B (belumosudil 200 mg tablet-fed) vs. Regimen A (belumosudil 200 mg tablet-fasting) and for Regimen B vs. Regimen C (belumosudil 200 mg capsule-fed) utilizing the Ratio of the Adjusted Geometric Means at 48 hours after dosing
Time frame: Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose
Pharmacokinetics: AUCs for the Relative Bioavailability of Regimen B/Regimen A and Regimen B/Regimen C by Ratio of the Adjusted Geometric Means at 48 Hours Post-dose
Analysis of the area under concentration-time curve for zero to infinity (AUC\[0-inf\]), and zero to last dose (AUC\[0-last\]) of the relative bioavailability of Regimen B (belumosudil 200 mg tablet-fed) vs. Regimen A (belumosudil 200 mg tablet-fasting) and for Regimen B vs. Regimen C (belumosudil 200 mg capsule-fed) utilizing the Ratio of the Adjusted Geometric Means at 48 hours after dosing
Time frame: Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose
Pharmacokinetics: Cmax of Dosing Regimen A (Tablets--Fasting) vs. Dosing Regimen B (Tablets--Fed) vs. Dosing Regimen C (Capsules--Fed) for KD025, KD025m1, and KD025m2 at 48 Hours Post-dose
Maximum concentration (Cmax) of parent drug (KD025), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) when administering a single dose of belumosudil 200 mg tablet to subjects who are fasting (Regimen A) compared to administering a single dose of belumosudil 200 mg tablet to subjects who are fed (Regimen B) compared to a single dose of belumosudil 200 mg capsule (two 100-mg capsules) to subjects who are fed (Regimen C) at 48 hours after dosing
Time frame: Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose
Pharmacokinetics: AUCs of Regimen A (Tablet--Fasting) vs. Dosing Regimen B (Tablet--Fed) vs. Dosing Regimen C (Capsule--Fed) for KD025, KD025m1, and KD025m2 for Belumosudil 200 mg at 48 Hours Post-dose
Area under concentration curve from zero to last dose (AUC\[0-last\]) and from zero to infinity (AUC\[0-inf\]) for parent drug (KD025), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) when administering a single dose of belumosudil 200 mg tablet to subjects who are fasting (Regimen A) compared to administering a single dose of belumosudil 200 mg tablet to subjects who are fed (Regimen B) compared to administering a single dose of 200 mg capsule (two 100-mg capsules) to subjects who are fed at 48 hours after dosing
Time frame: Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose
Pharmacokinetics: Lambda-z for Regimens A, B, and C for KD025, KD025m1, and KD025m2 at 48 Hours Post-dose
Slope of the regression line passing through the apparent elimination phase in a concentration-time plot (Lambda-z) for Regimen A, Regimen B, and Regimen C for for the parent drug (KD025), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) at 48 hours after dosing
Time frame: Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose
Pharmacokinetics: t(1/2), MRT(0-last), and MRT(0-inf) for Regimens A, B, and C for KD025, KD025m1, and KD025m2 at 48 Hours Post-dose
Apparent elimination half-life (t\[1/2\]), mean residence time from zero to last dose (MRT\[0-last\]), and MRT for zero to infinity (MRT\[0-inf\]) for Regimen A, Regimen B, and Regimen C for for the parent drug (KD025), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) at 48 hours after dosing
Time frame: Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose
Safety: Number of Subjects With TEAEs and SAEs
Number of subjects with treatment-emergent adverse events (TEAEs), severity and relationship to belumosudil, serious adverse events (SAEs), TEAEs leading to withdrawal from study, and deaths. Treatment-emergent adverse events (TEAEs) are AEs that are not present before the first dose of IMP or that are present before the first dose of IMP but worsen in intensity during exposure to IMP. Severity: mild = 1; moderate = 2; severe = 3; life-threatening = 4; and death = 5. Related to belumosudil defined as possibly related, probably related, and related.
Time frame: Approximately 1 month
Safety: Total Number of Participants With TEAEs, Related TEAEs, Leading to Withdrawal, Severe, Serious, Leading to Death
Total number of subjects who had treatment-emergent adverse events (TEAEs), TEAEs related to belumosudil, TEAEs leading to withdrawal of subject, severe TEAEs, serious TEAE (SAE), and TEAEs leading to death. Treatment-emergent adverse events (TEAEs) are AEs that are not present before the first dose of IMP or that are present before the first dose of IMP but worsen in intensity during exposure to IMP. Severity: mild = 1; moderate = 2; severe = 3; life-threatening = 4; and death = 5. Related to belumosudil defined as possibly related, probably related, and related.
Time frame: Approximately 1 month
Enrollment: 23 subjects
| Milestone | Cohort ABC | Cohort BCA | Cohort CAB |
|---|---|---|---|
| Started | 8 | 8 | 7 |
| Completed | 6 | 8 | 5 |
| Not completed | 2 | 0 | 2 |
| Withdrew: Significant liver elevation | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Illness of prohibited medication | 0 | 0 | 1 |
Maximum concentration (Cmax) of parent drug (KD025), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) when administering a single dose of belumosudil 200 mg tablet to subjects who are fasting (Regimen A) compared to administering a single dose of belumosudil 200 mg tablet to subjects who are fed (Regimen B) at 48 hours after dosing
| ng/mL | Regimen A | Regimen B |
|---|---|---|
| Cmax: KD025 | 821 ± 129.5 | 2100 ± 49.8 |
| Cmax: KD025m1 | 19.4 ± 51.6 | 25.8 ± 42.0 |
| Cmax: KD025m2 | 173 ± 122.6 | 412 ± 63.0 |
Area under concentration-time curve from zero to last dose of belumosudil 200 mg tablets (AUC\[0-last\]) and from zero to infinity (AUC\[0-inf\]) for Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) when administering a single dose of belumosudil 200 mg tablet to subjects who are fasting (Regimen A) compared to administering a single dose of belumosudil 200 mg tablet to subjects who are fed (Regimen B) at 48 hours after dosing
| (ng*h)/mL | Regimen A | Regimen B |
|---|---|---|
| AUC(0-last): KD025 | 4520 ± 121.3 | 9750 ± 49.3 |
| AUC(0-last): KD025m1 | 19.8 ± 150.6 | 45.2 ± 95.3 |
| AUC(0-last): KD025m2 | 550 ± 133.3 | 1320 ± 62.6 |
| AUC(0-inf): KD025 | 4910 ± 146.9 | 10100 ± 52.9 |
| AUC(0-inf): KD025m1 | 153 ± 0 | 98.7 ± 0 |
| AUC(0-inf): KD025m2 | 691 ± 76.7 | 1370 ± 62.6 |
Analysis of the maximum concentration (Cmax) of the relative bioavailability of Regimen B (belumosudil 200 mg tablet-fed) vs. Regimen A (belumosudil 200 mg tablet-fasting) and for Regimen B vs. Regimen C (belumosudil 200 mg capsule-fed) utilizing the Ratio of the Adjusted Geometric Means at 48 hours after dosing
| Ratio of Adjusted Geometric Means | Regimen B/Regimen A | Regimen B/Regimen C |
|---|---|---|
| Pharmacokinetics: Cmax for the Relative Bioavailability of Regimen B/Regimen A and Regimen B/Regimen C by Ratio of the Adjusted Geometric Means at 48 Hours Post-dose | 225.02 (176.08 to 287.57) | 119.38 (93.41 to 152.56) |
Analysis of the area under concentration-time curve for zero to infinity (AUC\[0-inf\]), and zero to last dose (AUC\[0-last\]) of the relative bioavailability of Regimen B (belumosudil 200 mg tablet-fed) vs. Regimen A (belumosudil 200 mg tablet-fasting) and for Regimen B vs. Regimen C (belumosudil 200 mg capsule-fed) utilizing the Ratio of the Adjusted Geometric Means at 48 hours after dosing
| Ratio of Adjusted Geometric Means | Regimen B/Regimen A | Regimen B/Regimen C |
|---|---|---|
| AUC(0-inf) | 179.58 (143.16 to 225.26) | 118.43 (97.16 to 144.36) |
| AUC(0-last) | 187.92 (154.07 to 229.21) | 117.57 (96.40 to 143.40) |
Maximum concentration (Cmax) of parent drug (KD025), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) when administering a single dose of belumosudil 200 mg tablet to subjects who are fasting (Regimen A) compared to administering a single dose of belumosudil 200 mg tablet to subjects who are fed (Regimen B) compared to a single dose of belumosudil 200 mg capsule (two 100-mg capsules) to subjects who are fed (Regimen C) at 48 hours after dosing
| ng/mL | Regimen A | Regimen B | Regimen C |
|---|---|---|---|
| Cmax: Parent Drug KD025 | 821 ± 129.5 | 2100 ± 49.8 | 1750 ± 38.2 |
| Cmax: KD025m1 | 19.4 ± 51.6 | 25.8 ± 42.0 | 20.6 ± 38.2 |
| Cmax: KD025m2 | 173 ± 122.6 | 412 ± 63.0 | 289 ± 76.5 |
Area under concentration curve from zero to last dose (AUC\[0-last\]) and from zero to infinity (AUC\[0-inf\]) for parent drug (KD025), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) when administering a single dose of belumosudil 200 mg tablet to subjects who are fasting (Regimen A) compared to administering a single dose of belumosudil 200 mg tablet to subjects who are fed (Regimen B) compared to administering a single dose of 200 mg capsule (two 100-mg capsules) to subjects who are fed at 48 hours after dosing
| (ng*h)/mL | Regimen A | Regimen B | Regimen C |
|---|---|---|---|
| AUC(0-last): KD025 | 4520 ± 121.3 | 9750 ± 49.3 | 8650 ± 42.7 |
| AUC(0-last): KD025m1 | 19.8 ± 150.6 | 45.2 ± 95.3 | 33.6 ± 106.9 |
| AUC(0-last): KD025m2 | 550 ± 133.3 | 1320 ± 62.6 | 1000 ± 95.5 |
| AUC(0-inf): KD025 | 4910 ± 146.9 | 10100 ± 52.9 | 8710 ± 42.2 |
| AUC(0-inf): KD025m1 | 153 ± 0 | 98.7 ± 0 | 213 ± 0 |
| AUC(0-inf): KD025m2 | 691 ± 76.7 | 1370 ± 62.6 | 1420 ± 47.7 |
Slope of the regression line passing through the apparent elimination phase in a concentration-time plot (Lambda-z) for Regimen A, Regimen B, and Regimen C for for the parent drug (KD025), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) at 48 hours after dosing
| 1/hour | Regimen A | Regimen B | Regimen C |
|---|---|---|---|
| KD025 | 0.0622 ± 1.5848 | 0.0993 ± 1.5293 | 0.0967 ± 1.4594 |
| KD025m1 | 0.3618 ± 0 | 0.3608 ± 0 | 0.1275 ± 0 |
| KD025m2 | 0.4159 ± 1.5248 | 0.3291 ± 1.7326 | 0.2523 ± 1.7385 |
Apparent elimination half-life (t\[1/2\]), mean residence time from zero to last dose (MRT\[0-last\]), and MRT for zero to infinity (MRT\[0-inf\]) for Regimen A, Regimen B, and Regimen C for for the parent drug (KD025), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) at 48 hours after dosing
| Hours | Regimen A | Regimen B | Regimen C |
|---|---|---|---|
| KD025: t(1/2) | 11.16 ± 1.58 | 6.98 ± 1.53 | 7.16 ± 1.46 |
| KD025m1: t(1/2) | 1.92 ± 0 | 1.92 ± 0 | 5.44 ± 0 |
| KD025m2: t(1/2) | 1.67 ± 1.52 | 2.11 ± 1.73 | 2.75 ± 1.74 |
| KD025: MRT(0-last) | 7.25 ± 1.39 | 5.70 ± 1.27 | 6.21 ± 1.22 |
| KD025m1: MRT(0-last) | 1.70 ± 1.61 | 2.45 ± 1.61 | 2.79 ± 1.57 |
| KD025m2: MRT(0-last) | 3.03 ± 1.32 | 3.99 ± 1.45 | 4.44 ± 1.34 |
| KD025: MRT(0-inf) | 9.35 ± 1.33 | 6.40 ± 1.27 | 7.18 ± 1.24 |
| KD025m1: MRT(0-inf) | 3.38 ± 0 | 4.39 ± 0 | 8.26 ± 0 |
| KD025m2: MRT(0-inf) | 3.46 ± 1.30 | 4.35 ± 1.46 | 4.86 ± 1.40 |
Number of subjects with treatment-emergent adverse events (TEAEs), severity and relationship to belumosudil, serious adverse events (SAEs), TEAEs leading to withdrawal from study, and deaths. Treatment-emergent adverse events (TEAEs) are AEs that are not present before the first dose of IMP or that are present before the first dose of IMP but worsen in intensity during exposure to IMP. Severity: mild = 1; moderate = 2; severe = 3; life-threatening = 4; and death = 5. Related to belumosudil defined as possibly related, probably related, and related.
| Participants | Regimen A | Regimen B | Regimen C | Overall |
|---|---|---|---|---|
| At least 1 TEAE | 6 | 3 | 5 | 9 |
| Reporting belumosudil-related TEAEs | 1 | 0 | 0 | 1 |
| TEAEs Leading to Withdrawal | 3 | 0 | 0 | 3 |
| Severe TEAEs | 1 | 0 | 0 | 1 |
| Serious TEAEs | 0 | 0 | 0 | 0 |
| TEAEs Leading to Death | 0 | 0 | 0 | 0 |
Total number of subjects who had treatment-emergent adverse events (TEAEs), TEAEs related to belumosudil, TEAEs leading to withdrawal of subject, severe TEAEs, serious TEAE (SAE), and TEAEs leading to death. Treatment-emergent adverse events (TEAEs) are AEs that are not present before the first dose of IMP or that are present before the first dose of IMP but worsen in intensity during exposure to IMP. Severity: mild = 1; moderate = 2; severe = 3; life-threatening = 4; and death = 5. Related to belumosudil defined as possibly related, probably related, and related.
| Participants | Regimen A | Regimen B | Regimen C | Overall |
|---|---|---|---|---|
| All TEAEs | 7 | 3 | 6 | 16 |
| TEAEs Related to Belumosudil | 1 | 0 | 0 | 1 |
| TEAEs Leading to Withdrawal | 3 | 0 | 0 | 3 |
| Severe TEAEs | 1 | 0 | 0 | 1 |
| Serious TEAEs (SAE) | 0 | 0 | 0 | 0 |
| TEAEs Leading to Death | 0 | 0 | 0 | 0 |
Collected over Approximately 1 month. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Regimen A | 0/23 (0%) | 0/23 (0%) | 6/23 (26.1%) |
| Regimen B | 0/20 (0%) | 0/20 (0%) | 3/20 (15%) |
| Regimen C | 0/22 (0%) | 0/22 (0%) | 5/22 (22.7%) |
| Event | Regimen A | Regimen B | Regimen C |
|---|---|---|---|
| HeadacheNervous system disorders | 0/23 | 1/20 | 1/22 |
| NasopharyngitisInfections and infestations | 0/23 | 1/20 | 0/22 |
| OropharyngealRespiratory, thoracic and mediastinal disorders | 0/23 | 1/20 | 0/22 |
| ParesthesiaNervous system disorders | 0/23 | 0/20 | 1/22 |
| SomnolenceNervous system disorders | 0/23 | 0/20 | 1/22 |
| FatigueGeneral disorders | 0/23 | 0/20 | 1/22 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/23 | 0/20 | 1/22 |
| Rash macularSkin and subcutaneous tissue disorders | 0/23 | 0/20 | 1/22 |
| Cervical radiculopathyNervous system disorders | 1/23 | 0/20 | 0/22 |
| Influenza-like illnessGeneral disorders | 1/23 | 0/20 | 0/22 |
| Age, Continuous(Years) | Cohort ABC | Cohort BCA | Cohort CAB | Total |
|---|---|---|---|---|
| Mean | 34.1 ± 11.0 | 32.3 ± 12.4 | 43.0 ± 9.0 | 36.2 ± 11.5 |
| Age, Continuous(Years) | Cohort ABC | Cohort BCA | Cohort CAB | Total |
|---|---|---|---|---|
| Median | 32.5 (20 to 53) | 27.5 (21 to 50) | 46.0 (30 to 54) | 33.0 (20 to 54) |
| Sex: Female, Male(Participants) | Cohort ABC | Cohort BCA | Cohort CAB | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 8 | 8 | 7 | 23 |
| Race (NIH/OMB)(Participants) | Cohort ABC | Cohort BCA | Cohort CAB | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 1 | 3 |
| White | 7 | 7 | 6 | 20 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| BMI (body mass index)(kg/m^2) | Cohort ABC | Cohort BCA | Cohort CAB | Total |
|---|---|---|---|---|
| Mean | 26.19 ± 2.67 | 25.79 ± 2.43 | 26.53 ± 3.35 | 26.15 ± 2.70 |
| BMI (body mass index)(kg/m^2) | Cohort ABC | Cohort BCA | Cohort CAB | Total |
|---|---|---|---|---|
| Median | 26.4 (22.4 to 29.3) | 26.0 (22.6 to 28.7) | 26.1 (22.1 to 30.0) | 26.10 (22.1 to 30.0) |
The record gives a start of Sep 2015, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2021, 6 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belumosudil